Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02868359
Other study ID # A0081354
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 2016
Est. completion date October 24, 2017

Study information

Verified date January 2019
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to evaluate the effect of pregabalin on patient reported outcomes compared with conventional analgesic care in chronic cervical pain patients with accompanying upper limb radiating pain (neuropathic component) treated in primary care settings under routine clinical practice.


Description:

Rational and background: Cervical pain with upper limb radiating pain(neuropathic component), such as cervical spondylosis radiculopathy or cervical spondylotic myelopathy, is one of the typical and common neuropathic pain. However, in Japan, large number of those patients are treated with NSAIDs without adequately assessing the cause of pain, despite that α2δ ligand, SNRI (Serotonin and Norepinephrine Reuptake Inhibitors ), and TCA (Tricyclic Antidepressants) are recommended in the clinical guidelines for neuropathic pain. Therefore, treatment satisfaction of these patients is low. This is currently a major issue in treatment for cervical pain with neuropathic component in Japan. In fact, our previous study which assessed the effect of pregabalin in low back pain patients with radiculopathy suggested that the selection of appropriate analgesics according to the cause of pain improved pain related sleep interference, pain and function. However, there are a few reports with regard to effect of pregabalin in cervical pain patients with neuropathic component. Therefore, we propose to conduct an observational study in order to assess the effects of pregabalin in cervical radiculopathy, when added to routine clinical care. The present study can encourage an understanding of the necessary of assessing cause of the pain, and treating with appropriate analgesics. Research objectives : To evaluate the effect of pregabalin comparing with the conventional analgesic care in chronic cervical pain patients with accompanying upper limb radiating pain(neuropathic component) treated in primary care settings under routine clinical practice. Study design: This is an 8-week, multicenter prospective non-interventional observational study. Subjects who have chronic cervical radiating pain patients with accompanying upper limb radiating pain (with a neuropathic component) and meet all other entry criteria are enrolled at baseline in the duration of study. Study arms are pregabalin with or without usual care vs. usual care (mono/combo therapy). The usual care are assumed NSAIDs, Antidepressants, weak opioids, acetaminophen etc. The analgesic treatment is determined by the clinical judgment of the physician in charge of patient management. This therapeutic choice is not related to the decision to take part in the study. All enrolled subjects will be received with analgesic treatment. The study requires 3 visits at least, baseline/enrollment visit, Week 4 visit and Week 8 visit (or discontinuation).


Recruitment information / eligibility

Status Completed
Enrollment 369
Est. completion date October 24, 2017
Est. primary completion date October 24, 2017
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: Subject who received the enough study information and signed informed consent form. Subject who had chronic pain with accompanying radiating pain to the superior limb beyond the elbow. Subject is male or female patient ?20 years old. Subject who reported neck pain with accompanying radiating pain to superior limb (12 weeks or greater in duration at Visit 0). Subject who is refractory to previous analgesics for 12 weeks and more. Subject who is able and willing to complete all study related assessment tools and complied with scheduled clinic visits and clinical study procedures. Subject whose pain NRS ?5 and PRSIS ?1 at baseline (based on recall over the past week). Exclusion Criteria: Subject who, in the opinion of the investigator, was not likely to complete the trial for whatever reason. Subject who was treated with Pregabalin within the past 12 weeks (on baseline). Subject who has been regularly treated cervical pain with nerve blocks (such as stellate ganglion block, epidural block, radicular block and trigger point injection etc.).

Study Design


Intervention

Other:
No Intervention
The study is observational.

Locations

Country Name City State
Japan Nakaicho Clinic Adachi Tokyo
Japan Ageo Medical Clinic Ageo Saitama
Japan Kyobashi Orthopaedic Clinic Chuo Tokyo
Japan Morishima Clinic Edogawa Tokyo
Japan Fujisawa Shonandai Hospital Fujisawa-shi Kanagawa
Japan Chihaya Hospital Fukuoka-shi Fukuoka
Japan Clinic for Sports Medicine and Nutrition Fukuokashi Fukuoka
Japan Kiheikai Yoh Orthopedic Clinic Fukuokashi Fukuoka
Japan Seiwa Orthopedics Surgery Internal Medicine Fukuokashi Fukuoka
Japan Fukushima Daiichi Hospital Fukusima
Japan Fukuoka Mirai Hospital Higashi-ku,Fukuoka Fukuoka
Japan Oomuro Orthopedic Clinic Himeji-shi Hyogo
Japan Satoh Orthopaedic Clinic Ichikawa Chiba
Japan Shiraishi Orthopaedic Clinic Ichikawa Chiba
Japan Oonishi Medical Clinic Kako-gun Hyogo
Japan Shinkoiwa Ekimae Sogo Clinic Katsushika Tokyo
Japan Ando Orthopaedics Hospital Kawasakishi Kanagawa
Japan Shin Komonji Hospital Kitakyusyu-shi Fukuoka
Japan Watanabe Orthopaedic Clinic Kobe Hyogo
Japan Meguro Seikeigeka Naika Meguro Tokyo
Japan Meguro Yuai Clinic Meguro Tokyo
Japan Takemoto Orthopaedic Clinic Ohta Tokyo
Japan Saga-ken Medical Center Koseikan Saga
Japan General Sagami Kosei Hospital Sagamiharashi Kanagawa
Japan Arai Orthopaedic Clinic Saitama Kanagawa
Japan Miyanomori Memorial Hospital Sapporoshi Hokkaido
Japan Ohimachi Orthopaedic Clinic Shinagawa Tokyo
Japan Shinjuku Research Park Clinic Shinnzyuku Tokyo
Japan Kouenji Orthopedic Clinic Suginami Tokyo
Japan Takasaki Pain Clinic Takasaki-shi Gunma
Japan Tokyo Rheumatism Pain Clinic Tokyo
Japan Daido Hospital Toshima Tokyo
Japan Saitoh Orthopedic Sports Clinic Yamato-shi Kanagawa

Sponsors (1)

Lead Sponsor Collaborator
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline at 8 weeks in Pain Related Sleep Interference Scale (PRSIS - Past Week Recall) The Pain Related Sleep Interference Scale (past week recall) consists of an 11-point numeric rating scale (NRS) ranging from 0 (pain did not interfere with sleep) to 10 (pain completely interfered with sleep). Subjects are to describe how their pain has interfered with their sleep during the past week by choosing the appropriate number between 0 and 10. Baseline, Visit 2 (week 4), Final visit (week 8 or discontinuation)
Secondary Change From Baseline in Neck Disability Index (NDI) The Neck Disability Index (NDI) is an index of how well patients with cervical pain are able to function with regard to daily activities. The score for the index ranges from 0 to 50 with a lower score indicating better function. In the event that a patient has used rescue medication within 12 hours of the clinic visit, the patient should respond to the questions based on their functional ability in the 24 hour period just preceding the use of rescue medication. Baseline, Visit 2 (week 4), Final visit (week 8 or discontinuation)
Secondary Change From Baseline in Pain Numeric Rating Scale (Pain NRS - past week recall) The Pain NRS (past week recall) consists of an 11-point numeric rating scale (NRS) ranging from 0 (no pain) to 10 (worst possible pain). Subjects are asked to describe their average pain during the past week by choosing the appropriate number between 0 and 10. Baseline, Visit 2 (week 4), Final visit (week 8 or discontinuation)
Secondary Change From Baseline in Euro Qol- 5 Dimensions -5 Level (EQ-5D-5L)-QOL-Score- The EQ-5D-5L is a copyrighted, subject-completed questionnaire designed to assess health-related quality of life in terms of a single index value or utility score. There are two components to the EQ-5D-5L: A Health State Profile and a Visual Analogue Scale (VAS). Recent guidance suggests that the Health State Profile and VAS should be administered together.
The Health State Profile is designed to record the subject's level of current health for five domains comprising a health profile: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Responses from the five domains are used to calculate a single utility index value.
Baseline, Visit 2 (week 4), Final visit (week 8 or discontinuation)
Secondary Change From Baseline in Euro Qol- 5 Dimensions -5 Level (EQ-5D-5L)-Visual Analogue Scale - The EQ-5D-5L is a copyrighted, subject-completed questionnaire designed to assess health-related quality of life in terms of a single index value or utility score. There are two components to the EQ-5D-5L: A Health State Profile and a Visual Analogue Scale (VAS). Recent guidance suggests that the Health State Profile and VAS should be administered together.
The Visual Analogue Scale (VAS) is designed to rate the subject's current health state on a scale from 0 to 100 where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.
Baseline, Visit 2 (week 4), Final visit (week 8 or discontinuation)
Secondary Clinical Global Impression of Change (CGIC) The CGIC assessment includes one question (1-7 scale) inquiring about the subject's improvement considering their current disease state. Final visit (week 8 or discontinuation)
Secondary Patient Global Impression of Change (PGIC) The PGIC is a subject-rated instrument that measures change in the subject's overall status on a 7-point scale. Scores range from 1 (very much improved) to 7 (very much worse). Final visit (week 8 or discontinuation)
Secondary Work Productivity and Activity Impairment Questionnaire: (WPAI: GH) The WPAI: GH is a self-administered questionnaire that measures the effect of general health and symptom severity on work productivity and regular activities. Unlike general health or disease-specific measures, the WPAI:GH assesses function-related endpoints to allow a measure of the economic impact of relative differences in either the safety or efficacy of therapeutic endpoints. In this study, the WPAI: GH will measure the effect of the patient's chronic cervical pain with accompanying upper limb pain (neuropathic component) on work productivity and regular activities. Final visit (week 8 or discontinuation)
See also
  Status Clinical Trial Phase
Recruiting NCT04699734 - Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Completed NCT05235191 - Effectiveness and Safety of Methadone Versus Placebo for the Control of Neuropathic Pain in Different Etiologies Phase 3
Completed NCT05845177 - Persistent Pain After Hip Replacement
Completed NCT05496205 - A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers Phase 1
Not yet recruiting NCT05949554 - Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.
Withdrawn NCT05052645 - Ear Acupuncture for Neuropathic Pain N/A
Completed NCT02930551 - Neuromas as the Cause of Pain N/A
Completed NCT02824588 - Working Memory Training for Chronic Neuropathic and Fibromyalgia Pain N/A
Completed NCT02866396 - Impact of Pregabalin in Chronic Users vs. a Perioperative Limited Prescription on Oxycodone Requirement
Active, not recruiting NCT02560545 - Cannabinoids Effects on the Pain Modulation System N/A
Enrolling by invitation NCT02485795 - Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management N/A
Not yet recruiting NCT02246517 - The Effect of N2O on Chronic Neuropathic Pain Patients Phase 0
Completed NCT02099890 - The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury Phase 3
Completed NCT01946555 - Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain N/A
Completed NCT01884662 - Virtual Walking for Neuropathic Pain in Spinal Cord Injury N/A
Completed NCT01718821 - Assessments on Current Pain Managements in Upper Gastrointestinal Cancer Patients N/A
Completed NCT01669967 - The Role of Intravenous (IV) Lidocaine in the Management of Chronic Neuropathic Pain of Peripheral Nerve Origin N/A
Completed NCT01207596 - Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain Phase 4
Completed NCT01201317 - A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy Phase 2